The Missing Link
in Modern
Breast Imaging
Despite advances in digital mammography, tomosynthesis, and AI-assisted interpretation, one fundamental element remains unchanged: breast tissue must first be properly positioned. MammoGRIP® is designed to deliver exactly that.
The MammoGRIP® Principle
The Numbers Behind
39 Million Mammograms a Year
Despite remarkable advances in digital mammography, tomosynthesis, and AI-assisted interpretation, one fundamental moment remains unchanged and underserved — the physical contact between the technologist's hands and the patient.
women
of women cite pain
as the reason they don't return for annual screening. Fear of discomfort is not a comfort issue — it is a cancer detection issue.
Whelehan et al., Breast 2013
of ALL image failures
caused by positioning deficiencies — the #1 cited category across ACR-accredited centers
Bassett et al., Radiology 2000
of all retakes
traced directly to positioning errors — nearly 1 in 2 avoidable with proper technique
Prieto et al., RPD 2015
global IMF average
Half of all mammograms miss the inframammary fold — a critical anatomical landmark for complete imaging
Spuur et al., Eur J Radiol 2018
Sensitivity drop for invasive breast cancer detection
When images fail positioning criteria, radiologists lose nearly 18 percentage points of diagnostic sensitivity — directly increasing the risk of missed cancers
Taplin et al., AJR 2002
"Better positioning is not a technical problem.
It is a grip problem."
39 million mammograms annually in the United States alone. One moment that determines the quality of every image.
Estimated 60–90M mammograms performed globally each year (screening + diagnostic) · US: BRFSS / NHIS / NMD · Europe: EUNICE / Eurostat · Global: GLOBOCAN 2022
MammoGRIP®: A Mammography-Specific
Positioning Technology
Applied to the mammography technologist's hands before breast positioning, MammoGRIP® is the only mammography solution of its kind — combining enhanced grip performance with antiseptic hand preparation in a single, workflow-integrated application designed to support breast imaging quality and patient comfort at the point of acquisition.
"The Invisible Glove"
The only mammography-specific positioning technology of its kind — applied to the technologist's hands, not the equipment.
Enhanced Grip Surface
Creates a gentle adhesive surface designed to improve tissue manipulation with less breast handling — intended to reduce the extent of contact needed for proper positioning.
Antiseptic Formulation
Benzalkonium chloride-based antiseptic formulation designed to replace examination gloves. Absorbs rapidly — no residue on patient or technologist.
Zero-Residue Formula
Alcohol-free, fragrance-free, water-free. Single-use per exam. No equipment modification. No training required. Immediate workflow integration.
Patented Technology
MammoGRIP® is the only mammography-specific positioning technology of its kind with clinical data supporting improved image quality.
Why Not Simply Use Gloves?
Standard examination gloves are barrier devices intended primarily for infection control. To the authors' knowledge, no published clinical studies have demonstrated improved mammographic positioning performance — improved IMF visualization, reduced retake rates, or improved image-quality metrics — through the use of standard examination gloves alone.
MammoGRIP® is not simply a grip aid and not simply an antiseptic product. It is a mammography-specific positioning technology — the only one of its kind with clinical data.
The MammoGRIP® Principle
Clinically Studied.
Independently Validated.
Two independent clinical studies demonstrate MammoGRIP®'s performance — one measuring objective image quality metrics, one capturing patient experience of comfort and adherence.
Study 01 — Image Quality
Englewood Health Pilot Study
Goldfischer M, Weiselberg C, Kim H, Williams K
Within-subject comparison of 50 women (ages 40–75) undergoing routine screening mammography. Each participant's MammoGRIP® mammogram was compared to her own prior historical mammogram using McNemar's test — eliminating inter-patient variability.
★ Statistically significant vs. historical mammograms (McNemar's test). Both IMF values exceed the global average of 52.4% (Spuur et al., Eur J Radiol 2018). Peer-reviewed publication forthcoming.
Study 02 — Patient Experience
Portugal Patient Experience Study
Bioflex and Akurey / MammoGRIP® · Lisbon Region
62 women underwent mammography with MammoGRIP®; 14 women consented to in-depth interviews. Pain is not merely a comfort issue — published systematic reviews demonstrate that 25%–46% of women who do not return for screening cite pain as the reason (Whelehan et al., Breast 2013).
Recognized reduced discomfort and less breast manipulation
Acknowledged fewer retakes compared to prior mammograms
Recognized fewer retakes improved diagnostic confidence and reduced radiation exposure
Felt confident undergoing the exam with MammoGRIP®
of technologists identified any problem with MammoGRIP® use
Educational Disclaimer: The Englewood Health Pilot Study (n=50) is a pilot study conducted at a single center; multicenter expansion is ongoing. Peer-reviewed publication is forthcoming in an indexed journal. The statistical significance achieved (p=0.029 right IMF; p=0.014 left IMF by McNemar's test) should be interpreted in the context of a within-subject pilot design.
AI Has Raised the Stakes —
MammoGRIP® Is the Foundational Layer
The emergence of AI-assisted screening has increased the importance of image quality rather than reduced it. Every AI benefit assumes the image was properly acquired — and that assumption starts with MammoGRIP®.
AI Reads After Acquisition
AI-assisted screening tools analyze images after they are acquired. The MASAI trial demonstrated AI-supported screening achieved 80.5% sensitivity vs 73.8% with a 12% reduction in interval cancer rate.
MASAI trial, 2024
But AI Assumes Image Quality
Suboptimal images led to inaccurate AI risk scores with unexpectedly large variability. AI-driven feedback systems assess quality after acquisition — they cannot fix what was never captured.
Alström et al., Radiat Prot Dosimetry 2026
MammoGRIP® Works During Acquisition
MammoGRIP® is designed to improve the physical quality of image acquisition. It is not a replacement for AI — it is the foundational layer upon which every downstream technology depends.
The MammoGRIP® Principle
"MammoGRIP® is not a replacement for AI or advanced imaging technologies — it is a complementary foundational layer upon which every downstream technology depends."
One Technology.
Transformative Impact Across Roles.
Dignity, Comfort, and Confidence
MammoGRIP® is designed to reduce the extent of breast manipulation required for positioning, which may support patient comfort and reduce anxiety. 93% of patients in the Portugal study recognized reduced discomfort. When women have better experiences, they return for screening.
- Less breast manipulation
- Reduced discomfort and anxiety
- Increased screening adherence
- Positive experience shared with others
Professional Confidence and Control
MammoGRIP® is designed to give technologists enhanced grip control during positioning — supporting more consistent results with less physical effort. In the Portugal study, 0% of technologists identified any problem with MammoGRIP® use.
- Enhanced grip precision
- Designed to reduce retake rates
- No equipment changes required
- Integrates into existing workflow instantly
Efficiency, Quality, and ACR Compliance
Intended to reduce positioning-related retakes, MammoGRIP® may support ACR accreditation performance benchmarks, extended equipment longevity, and increased patient throughput — with estimated throughput improvements of ~1,000 additional patients per year at 10,000-exam facilities.
- Designed to reduce retake rates
- Supports ACR accreditation criteria
- Extended X-ray tube life
- Glove cost elimination
Population Health and Earlier Detection
Improved positioning quality may directly support earlier cancer detection at the population level. At approximately $2 per patient, MammoGRIP® approaches cost-neutrality when operational savings are factored in — making adoption economically rational even before considering clinical benefits.
- Earlier-stage cancer detection
- Improved screening adherence metrics
- Cost-neutral economics
- Public health alignment
A Better Experience
From First Contact to Final Image
Scheduling
Patient schedules routine screening mammogram. With appropriate pre-visit communication about the imaging process, anxiety and anticipation of pain may be reduced from the outset.
Check-In & Preparation
Patient arrives and completes routine intake. Staff provide information about the imaging procedure and what to expect during positioning.
MammoGRIP® Applied
MammoGRIP® AppliedThe mammography technologist applies MammoGRIP® to their hands before the positioning exam. The antiseptic formulation replaces standard examination gloves — the single-use solution absorbs rapidly, leaving no residue.
Imaging with Precision
With MammoGRIP® applied, the technologist is designed to achieve enhanced control during breast positioning, supporting consistent tissue inclusion, IMF visualization, and overall image quality.
Positive Outcome
Fewer retakes. Reduced discomfort. A better experience — for both patient and technologist. When patients have positive experiences, they return for screening on schedule.
Patient testimonial — MammoGRIP® Clinical Program
A Compelling
Cost-Benefit Case
At approximately $2 per patient, MammoGRIP® approaches cost-neutrality when operational savings are factored in — making adoption economically rational even before considering clinical and public-health benefits.
Retake Reduction Savings
Reduced film costs, X-ray tube wear, technologist time, and patient scheduling per avoided retake
Extended X-Ray Tube Life
Fewer retakes directly extend equipment longevity and reduce capital expenditure cycles
Increased Patient Throughput
~1,000 additional patients per year at a 10,000-exam baseline — revenue generation from expanded capacity
Glove Cost Elimination
MammoGRIP®'s antiseptic formulation is designed to eliminate the need for examination gloves during positioning
Downstream Cost Avoidance
Earlier cancer detection through improved image quality may reduce downstream treatment costs for late-stage disease
Designed to Address a Persistent
Challenge in Breast Imaging
MammoGRIP® was developed to address one of the most persistent challenges in mammography and breast imaging: achieving reliable positioning while improving comfort, confidence, and consistency throughout the patient experience.
Today, MammoGRIP® is being introduced internationally as part of a broader effort to enhance mammography patient comfort, breast imaging workflow, and clinical efficiency — bringing meaningful innovation to every mammography exam, for every patient, in every screening environment.
A Coordinated
Global Commercialization Architecture
MammoGRIP® is positioned at an inflection point between early commercialization and broader international scale — with regulatory approvals in three major jurisdictions and active commercialization underway across multiple territories.
Brazil & Latin America
Alphattitude Capital
First major commercialization territory. 9.5–12M annual mammograms. Exclusive licensee focused on Brazil and full Latin American expansion. Pathway to PDP/PPP public-sector partnerships.
Iberian Peninsula
Local Trade Partner · To Be Disclosed
European gateway providing CE Mark market access, institutional credibility, and strategic connectivity. Covers Spain's autonomous regions and Portugal's mature healthcare system.
Africa (Continental)
Confidential Principal + Regional Sublicensees
Performance-based continental licensing with two regional sub-licensees covering North Africa and Sub-Saharan Africa independently. Regulatory activities underway in selected jurisdictions.
United States
Controlled Commercialization
Most strategically significant long-term market. Pursuing carefully controlled commercialization strategy with exploratory discussions ongoing with a major global imaging industry participant.
Europe (Broader)
Licensee candidates under evaluation
Building on Iberian CE Mark foundation. Bioflex actively interviewing licensee candidates for additional European countries using a rigorous 12–24 month selection framework.
The Brazil–Iberian Axis
Brazil and the Iberian Peninsula were not selected as independent opportunities. They were selected because of the strategic relationship between them. The historical, cultural, linguistic, economic, and business connections linking Portugal, Spain, and Latin America create opportunities for knowledge transfer, partnership development, market intelligence sharing, and coordinated expansion strategies.
From Concept to
Global Commercialization
Innovative concept developed
Clinical studies completed
Regulatory pathway established
International commercialization initiated
Global expansion underway
Ongoing market development
Connect With Our
Clinical Team
We welcome inquiries from healthcare providers, imaging center administrators, distribution partners, and clinical professionals interested in learning more about MammoGRIP® or exploring partnership opportunities.
Commercialization & Global Expansion
MammoGRIP® is supported by Bioflex USA Life Technologies, a medical technology commercialization platform dedicated to advancing innovative healthcare solutions through strategic partnerships, licensing, clinical development, and international expansion.
This framework enables MammoGRIP® to expand its impact across healthcare systems worldwide while maintaining focus on clinical excellence, breast imaging innovation, and patient outcomes.
Request Clinical Information
We'll respond within 1–2 business days